Immunomic Therapeutics, Inc (ITI) and BioHealth Innovation are partnering to provide funding opportunities and more to the winner of their Cancer Discovery Incubator Award. Applications are available now and the deadline to apply is by December 31, 2016. The Incubator’s mission is to accelerate growth and development of ventures designed on the field of oncological health.
Apart from receiving funding, the Award winner will be able to develop a proof-of-concept experiment in one of the Immunomic laboratories. Winners will also receive lab equipment and a year-long mentorship with the executive team of Immunomic.
“It is exciting to pay it forward and empower a new innovator to work in Maryland,” says Dr. William Hearl the CEO of Immunomic Therapeutics. After a successful $315 million deal with Astellas Pharma, Inc, Immunomics was able to develop its VAMP-Lax platform technology in allergy prevention and treatment using. Now with partner BioHealth Innovation, Immunomic is giving back to the region's growing scientific community with the Cancer Discovery Incubator Award. It’s intended to bring a measurable change in oncological health.
Hearl also adds that “If it wasn’t for the help of a similar incubator opportunity, we (Immunomic) might not be where we are today.”
The winner of the Cancer Discovery Incubator Award will be announced in February 2017. For more information regarding the Incubator, visit here.